Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Immunotherapy. 2013 Feb;5(2):155–167. doi: 10.2217/imt.12.155

Table 1.

Summary of completed trials using EGF receptor vIII peptide vaccines.

Study Phase Patients (n) Antigen Trial results Ref.
Sampson et al. (2010) II 18 EGFRvIII TTP 14.2 months
Median survival 26 months		 [33]
Del Vecchio et al. (2012) (preliminary results only) II 21 EGFRvIII Median survival 23.6 months [35]

EGFR: EGF receptor; TTP: Time to progression.